Pre-Clinical Findings from Organovo Indicate 3D-Printed Biotissue Successfully Implanted into Mice

Published by , December 27, 2016 12:46 pm

(3DPrintingIndustry) New pre-clinical findings from 3D bioprinting company Organovo (NASDAQ:ONVO) indicate it will be three-five years before the U.S. based Organovo applies for clearance of their liver tissue. However,that is still sooner than perhaps even the FDA had in mind. Pre-clinical trial data shows that 3D bioprinted liver tissue has been successfully planted into lab-bred mice. The human liver-cell tissue shows regular functionality and, at this stage, is being explored as a suitable patch for the organ.
In a statement from Organovo’s preclinical development team, chief strategy officer and executive vice president Eric Michael David explains, ‘Our preclinical data show rapid vascularization and tissue engraftment,’ – meaning that the 3D printed tissue encouraged the growth of blood vessels and fused to mice’s bone marrow.

Tags: ,